Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Further insight into AE37 peptide vaccination in prostate cancer.

Anastasopoulou EA, Voutsas IF.

Future Sci OA. 2017 May 11;3(3):FSO192. doi: 10.4155/fsoa-2017-0005. eCollection 2017 Aug. No abstract available.

2.

Immune profiling of melanoma tumors reflecting aggressiveness in a preclinical model.

Fortis SP, Mahaira LG, Anastasopoulou EA, Voutsas IF, Perez SA, Baxevanis CN.

Cancer Immunol Immunother. 2017 Dec;66(12):1631-1642. doi: 10.1007/s00262-017-2056-1. Epub 2017 Sep 4.

PMID:
28871365
3.

Prothymosin Alpha: An Alarmin and More...

Samara P, Karachaliou CE, Ioannou K, Papaioannou NE, Voutsas IF, Zikos C, Pirmettis I, Papadopoulos M, Kalbacher H, Livaniou E, Tsitsilonis OE, Voelter W.

Curr Med Chem. 2017;24(17):1747-1760. doi: 10.2174/0929867324666170518110033. Review.

PMID:
28521686
4.

Potential Prognostic Molecular Signatures in a Preclinical Model of Melanoma.

Fortis SP, Anastasopoulou EA, Voutsas IF, Baxevanis CN, Perez SA, Mahaira LG.

Anticancer Res. 2017 Jan;37(1):143-148.

PMID:
28011484
5.

Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.

Voutsas IF, Anastasopoulou EA, Tzonis P, Papamichail M, Perez SA, Baxevanis CN.

J Immunother Cancer. 2016 Nov 15;4:75. doi: 10.1186/s40425-016-0183-4. eCollection 2016.

6.

MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4(+) T-cells.

Anastasopoulou EA, Voutsas IF, Papamichail M, Baxevanis CN, Perez SA.

Oncoimmunology. 2016 May 2;5(7):e1178439. doi: 10.1080/2162402X.2016.1178439. eCollection 2016 Jul.

7.

A flow cytometric approach for studying alterations in the cytoplasmic concentration of calcium ions in immune cells following stimulation with thymic peptides.

Papaioannou NE, Voutsas IF, Samara P, Tsitsilonis OE.

Cell Immunol. 2016 Apr;302:32-40. doi: 10.1016/j.cellimm.2016.01.004. Epub 2016 Jan 7.

PMID:
26790897
8.

A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit.

Anastasopoulou EA, Voutsas IF, Keramitsoglou T, Gouttefangeas C, Kalbacher H, Thanos A, Papamichail M, Perez SA, Baxevanis CN.

Cancer Immunol Immunother. 2015 Sep;64(9):1123-36. doi: 10.1007/s00262-015-1717-1. Epub 2015 May 31.

PMID:
26026288
9.

Immune biomarkers: how well do they serve prognosis in human cancers?

Baxevanis CN, Anastasopoulou EA, Voutsas IF, Papamichail M, Perez SA.

Expert Rev Mol Diagn. 2015 Jan;15(1):49-59. doi: 10.1586/14737159.2015.965684. Epub 2014 Oct 27. Review.

PMID:
25345403
10.

New use for old drugs? Prospective targets of chloroquines in cancer therapy.

Vlahopoulos S, Critselis E, Voutsas IF, Perez SA, Moschovi M, Baxevanis CN, Chrousos GP.

Curr Drug Targets. 2014;15(9):843-51. Review.

PMID:
25023646
11.

Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies.

Baxevanis CN, Voutsas IF, Tsitsilonis OE.

Immunotherapy. 2013 May;5(5):497-511. doi: 10.2217/imt.13.24. Review.

PMID:
23638745
12.

Chemotherapy ± cetuximab modulates peripheral immune responses in metastatic colorectal cancer.

Xynos ID, Karadima ML, Voutsas IF, Amptoulach S, Skopelitis E, Kosmas C, Gritzapis AD, Tsavaris N.

Oncology. 2013;84(5):273-83. doi: 10.1159/000343282. Epub 2013 Feb 22.

PMID:
23445638
13.

Gamma-irradiation induces HER-2/neu overexpression in breast cancer cell lines and sensitivity to treatment with trastuzumab.

Voutsas IF, Mahaira LG, Fotopoulou K, Kapranos N, Reclos JG, Gritzapis AD, Papamichail M, Perez SA, Baxevanis CN.

Int J Radiat Biol. 2013 May;89(5):319-25. doi: 10.3109/09553002.2013.765617. Epub 2013 Feb 1.

PMID:
23311575
14.

Ovarian malignant ascites-derived lymphocytes stimulated with prothymosin α or its immunoactive decapeptide lyse autologous tumour cells in vitro and retard tumour growth in SCID mice.

Voutsas IF, Pistamaltzian N, Tsiatas ML, Skopeliti M, Katsila T, Mavrothalassiti I, Spyrou S, Dimopoulos MA, Tsitsilonis OE, Bamias A.

Eur J Cancer. 2013 May;49(7):1706-14. doi: 10.1016/j.ejca.2012.11.037. Epub 2012 Dec 28.

PMID:
23276721
15.

Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice.

Gritzapis AD, Voutsas IF, Baxevanis CN.

Cancer Immunol Immunother. 2012 Mar;61(3):397-407. doi: 10.1007/s00262-011-1113-4. Epub 2011 Sep 18.

PMID:
21928125
16.

Combined treatment with bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients.

Tsavaris N, Voutsas IF, Kosmas C, Gritzapis AD, Baxevanis CN.

Invest New Drugs. 2012 Feb;30(1):395-402. doi: 10.1007/s10637-010-9533-0. Epub 2010 Sep 7.

PMID:
20820907
17.

HER-2/neu as a target for cancer vaccines.

Baxevanis CN, Voutsas IF, Gritzapis AD, Perez SA, Papamichail M.

Immunotherapy. 2010 Mar;2(2):213-26. doi: 10.2217/imt.09.89. Review.

PMID:
20635929
18.

Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.

Gritzapis AD, Voutsas IF, Lekka E, Papamichail M, Baxevanis CN.

Cancer Res. 2010 Apr 1;70(7):2686-96. doi: 10.1158/0008-5472.CAN-09-2517. Epub 2010 Mar 16.

19.

Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties.

Gritzapis AD, Voutsas IF, Lekka E, Tsavaris N, Missitzis I, Sotiropoulou P, Perez S, Papamichail M, Baxevanis CN.

J Immunol. 2008 Jul 1;181(1):146-54.

20.

Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain.

Voutsas IF, Gritzapis AD, Mahaira LG, Salagianni M, von Hofe E, Kallinteris NL, Baxevanis CN.

Int J Cancer. 2007 Nov 1;121(9):2031-41.

21.

A novel quantitative flow cytometric method for measuring glucocorticoid receptor (GR) in cell lines: correlation with the biochemical determination of GR.

Voutsas IF, Gritzapis AD, Alexis MN, Katsanou ES, Perez S, Baxevanis CN, Papamichail M.

J Immunol Methods. 2007 Jul 31;324(1-2):110-9. Epub 2007 Jun 8.

PMID:
17582432
22.

Combining immunological and molecular data to assess phylogenetic relations of some Greek Podarcis species.

Valakos ED, Kourkouli A, Skopeliti M, Pafilis P, Poulakakis N, Voutsas IF, Lymberakis P, Simou C, Voelter W, Tsitsilonis OE.

Comp Biochem Physiol B Biochem Mol Biol. 2007 May;147(1):1-10. Epub 2007 Feb 21.

PMID:
17347009
23.

Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors.

Sotiriadou NN, Kallinteris NL, Gritzapis AD, Voutsas IF, Papamichail M, von Hofe E, Humphreys RE, Pavlis T, Perez SA, Baxevanis CN.

Cancer Immunol Immunother. 2007 May;56(5):601-13. Epub 2006 Sep 8.

PMID:
16960693
24.

The immunologically active site of prothymosin alpha is located at the carboxy-terminus of the polypeptide. Evaluation of its in vitro effects in cancer patients.

Skopeliti M, Voutsas IF, Klimentzou P, Tsiatas ML, Beck A, Bamias A, Moraki M, Livaniou E, Neagu M, Voelter W, Tsitsilonis OE.

Cancer Immunol Immunother. 2006 Oct;55(10):1247-57. Epub 2006 Feb 2.

PMID:
16453152
25.

Synergy between interleukin-2 and prothymosin alpha for the increased generation of cytotoxic T lymphocytes against autologous human carcinomas.

Voutsas IF, Baxevanis CN, Gritzapis AD, Missitzis I, Stathopoulos GP, Archodakis G, Banis C, Voelter W, Papamichail M.

Cancer Immunol Immunother. 2000 Oct;49(8):449-58.

PMID:
11043852
26.

Compromised anti-tumor responses in tumor necrosis factor-alpha knockout mice.

Baxevanis CN, Voutsas IF, Tsitsilonis OE, Tsiatas ML, Gritzapis AD, Papamichail M.

Eur J Immunol. 2000 Jul;30(7):1957-66.

27.

Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor.

Baxevanis CN, Voutsas IF, Tsitsilonis OE, Gritzapis AD, Sotiriadou R, Papamichail M.

J Immunol. 2000 Apr 1;164(7):3902-12.

28.

Increased generation of autologous tumor-reactive lymphocytes by anti-CD3 monoclonal antibody and prothymosin alpha.

Baxevanis CN, Spanakos G, Voutsas IF, Gritzapis AD, Tsitsilonis OE, Mamalaki A, Papamichail M.

Cancer Immunol Immunother. 1999 May-Jun;48(2-3):71-84.

PMID:
10414460
29.

Mistletoe lectin I-induced effects on human cytotoxic lymphocytes. I. Synergism with IL-2 in the induction of enhanced LAK cytotoxicity.

Baxevanis CN, Voutsas IF, Soler MH, Gritzapis AD, Tsitsilonis OE, Stoeva S, Voelter W, Arsenis P, Papamichail M.

Immunopharmacol Immunotoxicol. 1998 Aug;20(3):355-72.

PMID:
9736441
30.

The prognostic value of alpha-thymosins in breast cancer.

Tsitsilonis OE, Bekris E, Voutsas IF, Baxevanis CN, Markopoulos C, Papadopoulou SA, Kontzoglou K, Stoeva S, Gogas J, Voelter W, Papamichail M.

Anticancer Res. 1998 May-Jun;18(3A):1501-8.

PMID:
9673361

Supplemental Content

Loading ...
Support Center